GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital MarketBusiness Wire • 02/11/21
GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENTPRNewsWire • 12/21/20